Bad liver and a broken heart.
In this issue of Blood, the CORDELIA study presented by Pennell and colleagues shows that deferasirox (DFX; Exjade, Novartis) is not inferior to deferoxamine (DFO; Desferal, Novartis) for the removal of cardiac iron in β-thalassemia. CORDELIA also supports previous findings that efficacy of cardiac iron removal is better if liver iron concentration (LIC) is low.